Aiconomy

AI in Drug Discovery

The use of AI to accelerate pharmaceutical research by predicting molecular structures, identifying drug candidates, and optimizing clinical trial design — potentially reducing the $2.6 billion average cost of bringing a drug to market.

Over 100 AI-discovered drugs are currently in clinical trials. Insilico Medicine's AI-designed drug entered Phase 2 trials in 2023 — the first AI-designed drug to reach that stage. AI can reduce early-stage drug discovery timelines from 4-5 years to under 12 months. DeepMind's AlphaFold predicted the 3D structure of virtually all known proteins, providing a foundation for structure-based drug design. The AI in drug discovery market is projected to reach $8.2 billion by 2028. Major pharma companies including Pfizer, Roche, and Novartis have all established AI drug discovery partnerships.

Live Data

25,173AI Patent Filings This Year

AI Economy Pulse

Every Friday: the 3 AI data points that actually matter this week. Free, forever.

Built on data from Stanford HAI, IEA, OECD & IMF

Latest: “AI Investment Hits $42B in Q1 2026 — Here's Where It Went”

No spam, ever. Unsubscribe anytime.